Peer-reviewed Phase 3 TRANSCEND-T2D-1 demonstrated glycaemic and weight efficacy in adults with type 2 diabetes. Positive TRIUMPH Phase 3 obesity results have also been reported, although several remain sponsor/congress topline rather than full peer-reviewed publications.
Regulatory status
Not approved by any regulatory agency. Lilly stated in July 2026 that it plans a U.S. Biologics License Application submission in Q1 2027.
Main limitations
Retatrutide is not yet approved; source maturity differs across Phase 3 results, and long-term cardiovascular, renal and rare-event safety outcomes remain incomplete.
Safety
Gastrointestinal adverse effects and dose-related tolerability issues remain important; heart-rate increases have been observed. Longer-term and rare-event safety continue to be studied.
i
Retatrutide now has multiple positive Phase 3 trials across obesity and type 2 diabetes. TRANSCEND-T2D-1 is peer reviewed; several TRIUMPH results remain sponsor/congress topline data. It remains investigational.
What the evidence actually supports
✓Phase 3 efficacy has been demonstrated in obesity/overweight and type 2 diabetes populations.
✓A peer-reviewed Phase 3 diabetes trial supports direct human glycaemic and weight effects.
✓Additional obesity, knee osteoarthritis pain and sleep-apnea signals have been reported from the TRIUMPH programme.
What is not established / key limitations
×Regulatory approval has not been granted.
×Not all pivotal Phase 3 results are yet available as full peer-reviewed publications.
×Long-term cardiovascular, renal and rare-event benefit-risk remains under study; cross-trial comparisons do not establish superiority over other medicines.
Selected study & evidence records
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Gastrointestinal adverse effects and dose-related tolerability issues remain important; heart-rate increases have been observed. Longer-term and rare-event safety continue to be studied.
GI symptoms, dose-related tolerability issues, heart-rate increase; long-term risk profile remains under study.
Technical details
Mechanism / biologyActivates GIP, GLP-1 and glucagon receptors, affecting appetite, glycaemia and energy balance.
Route / formulation boundaryEvidence applies to trial-grade retatrutide, not to unverified research-market vials or pens.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published Phase 2 human trial regimen. See dosing_evidence records for route, regimen, population, duration and source.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
